Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Nets $47M in Public Stock Offering

NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market on Monday that it has closed its previously announced underwritten public offering of 4 million shares of common stock at a price of $12.50 per share.

Net proceeds were approximately $46.8 million after deducting underwriting discounts, commissions, and the estimated expenses of the offering. JP Morgan and UBS Investment Bank acted as joint book-running managers and Baird acted as lead manager.

NanoString intends to use the money for the development and launch of its Digital Spatial Profiling platform, the continued commercialization of its portfolio of nCounter-based products, and for general corporate purposes and working capital.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.